Alessandro Santos Farias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessandro Santos Farias has a total of 695 co-authors. Here are the top co-authors by number of shared publications:
- Adriel Santos Moraes
Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil
15 shared publications - Leonilda Maria Barbosa Santos
Unidade de Neuroimunologia, Dept.Genética, Evolução, Microbiologia e Imunologia, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
15 shared publications Fernando Pradella
University of Campinas
12 shared publicationsElaine C. Oliveira
Neuroimmunology Unit Department of Genetics, Evolution and Bioagents Institute of Biology University of Campinas Campinas Brazil
10 shared publications- Fernando Cendes
Department of Neurology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
10 shared publications - Felipe von Glehn
Faculty of Medicine, University of Brasília (UNB), Brasília 70910-900, Brazil
8 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7366
Comparative Transcriptomic Analysis of Oral Squamous Cell Carcinoma with Progressive Cisplatin Resistance
Therapy resistance remains a major cause of cancer-related mortality. Cisplatin (cis-diamminedichloroplatinum, CDDP) is a first-line chemotherapeutic agent for oral cancer, but intrinsic and acquired resistance substantially limit its clinical efficacy. Epithelial–mesenchymal transition (EMT) has been associated with drug resistance across multiple tumor types; however, its involvement in cisplatin resistance in oral cancer remains incompletely understood. Here, we established an in vitro model of cisplatin resistance using the squamous cell carcinoma 9 (SCC-9) cell line and generated two populations with distinct resistance levels. We observed morphological and transcriptional changes consistent with EMT-related features, including increased mRNA expression of Vimentin, SNAIL1, ZEB1, ZEB2, and CDH2. Resistant cells also exhibited reduced proliferation, whereas the intermediately resistant population, cisplatin-resistant 4 (CPR4), showed greater wound closure, suggesting enhanced migratory behavior and features consistent with a hybrid-like EMT state. Conversely, the more resistant subline, cisplatin-resistant 8 (CPR8), exhibited a more stationary phenotype. Transcriptomic profiling by RNA sequencing (RNA-seq) revealed extensive differential gene expression associated with EMT and cisplatin resistance. Functional enrichment analyses identified Gene Ontology (GO) terms related to cell adhesion, extracellular matrix organization, and calcium ion binding, while Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed enrichment of PI3K/Akt signaling. Together, our findings support a dynamic model in which distinct EMT-related transcriptional states are associated with different levels of cisplatin resistance. This study provides insights into transcriptional changes associated with resistance acquisition and highlights candidate genes and pathways for further investigation and functional validation in oral cancer.
- 18 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7366
Open AccessComparative Transcriptomic Analysis of Oral Squamous Cell Carcinoma with Progressive Cisplatin Resistance
Therapy resistance remains a major cause of cancer-related mortality. Cisplatin (cis-diamminedichloroplatinum, CDDP) is a first-line chemotherapeutic agent for oral cancer, but intrinsic and acquired resistance substantially limit its clinical efficacy. Epithelial–mesenchymal transition (EMT) has been associated with drug resistance across multiple tumor types; however, its involvement in cisplatin resistance in oral cancer remains incompletely understood. Here, we established an in vitro model of cisplatin resistance using the squamous cell carcinoma 9 (SCC-9) cell line and generated two populations with distinct resistance levels. We observed morphological and transcriptional changes consistent with EMT-related features, including increased mRNA expression of Vimentin, SNAIL1, ZEB1, ZEB2, and CDH2. Resistant cells also exhibited reduced proliferation, whereas the intermediately resistant population, cisplatin-resistant 4 (CPR4), showed greater wound closure, suggesting enhanced migratory behavior and features consistent with a hybrid-like EMT state. Conversely, the more resistant subline, cisplatin-resistant 8 (CPR8), exhibited a more stationary phenotype. Transcriptomic profiling by RNA sequencing (RNA-seq) revealed extensive differential gene expression associated with EMT and cisplatin resistance. Functional enrichment analyses identified Gene Ontology (GO) terms related to cell adhesion, extracellular matrix organization, and calcium ion binding, while Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed enrichment of PI3K/Akt signaling. Together, our findings support a dynamic model in which distinct EMT-related transcriptional states are associated with different levels of cisplatin resistance. This study provides insights into transcriptional changes associated with resistance acquisition and highlights candidate genes and pathways for further investigation and functional validation in oral cancer.
- Open Access
- 19 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1686572
Vaccination and COVID-19: impact on long-COVID
Long- and post-COVID-19 syndromes have emerged as a significant global health challenge, with millions of individuals experiencing persistent or the development of new symptoms after a long period of an initial SARS-CoV-2 infection. These symptoms are multisystemic and may indicate changes in the respiratory, neurological, cardiovascular and gastrointestinal systems, in addition to prolonged fatigue. Vaccination has played a crucial role in reducing severe disease and mortality, but the impact of the different vaccine combinations on the development and resolution of Long COVID remains a topic of debate. This review synthesizes current evidence on how different vaccine platforms, dosing strategies and booster doses influence the immunological response, protection, incidence, severity, and persistence of Long COVID symptoms. We discuss key immunological mechanisms by which vaccination may modulate and protect post-COVID syndrome outcomes, including its effects on viral clearance, immune response reprogramming, inflammation, and autoimmunity, seeking to combat misinformation and concepts spread by fake news. The review also highlights controversies and research gaps, such as variability in vaccine response among different populations and the role in the selection of more transmissible and virulent SARS-CoV-2 variants, as well as the potential differences between vaccine-induced and infection-induced immunity, and the role of pre-existing immune conditions in this scenario.
- 19 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1686572
Open AccessVaccination and COVID-19: impact on long-COVID
Long- and post-COVID-19 syndromes have emerged as a significant global health challenge, with millions of individuals experiencing persistent or the development of new symptoms after a long period of an initial SARS-CoV-2 infection. These symptoms are multisystemic and may indicate changes in the respiratory, neurological, cardiovascular and gastrointestinal systems, in addition to prolonged fatigue. Vaccination has played a crucial role in reducing severe disease and mortality, but the impact of the different vaccine combinations on the development and resolution of Long COVID remains a topic of debate. This review synthesizes current evidence on how different vaccine platforms, dosing strategies and booster doses influence the immunological response, protection, incidence, severity, and persistence of Long COVID symptoms. We discuss key immunological mechanisms by which vaccination may modulate and protect post-COVID syndrome outcomes, including its effects on viral clearance, immune response reprogramming, inflammation, and autoimmunity, seeking to combat misinformation and concepts spread by fake news. The review also highlights controversies and research gaps, such as variability in vaccine response among different populations and the role in the selection of more transmissible and virulent SARS-CoV-2 variants, as well as the potential differences between vaccine-induced and infection-induced immunity, and the role of pre-existing immune conditions in this scenario.
- Open Access
- 7 August 2025
- Published by Springer Nature in Research Square
STAT5/Runx3 axis mediates cytotoxic activity in CD4+ T cells during early neuroinflammation
CD4+ T cells are crucial for the development of autoimmune neuroinflammation in mice and are widely held to orchestrate the inflammatory cascade and immunopathology. Here, we show that auto-aggressive CD4⁺ T cells acquire a cytotoxic phenotype (CD4-CTL) and function during the early phase of relapsing-remitting multiple sclerosis (RRMS) and in experimental autoimmune encephalomyelitis (EAE). We identify the enhanced activation of the STAT5–Runx3 axis as a key driver of CD4-CTL development and maintenance. Notably, cytotoxic activity becomes more pronounced once these cells infiltrate the central nervous system (CNS). Importantly, a cytotoxic signature in peripheral CD4⁺ T cells reliably distinguishes early-stage RRMS patients from healthy controls. Mechanistically, CD4-CTLs share core molecular programs with effector CD8⁺ T cells. Together, our findings reveal potential biomarkers for early multiple sclerosis (MS) diagnosis, tools for monitoring treatment response, and targets for novel therapeutic strategies
- 7 August 2025
- Published by Springer Nature in Research Square
Open AccessSTAT5/Runx3 axis mediates cytotoxic activity in CD4+ T cells during early neuroinflammation
CD4+ T cells are crucial for the development of autoimmune neuroinflammation in mice and are widely held to orchestrate the inflammatory cascade and immunopathology. Here, we show that auto-aggressive CD4⁺ T cells acquire a cytotoxic phenotype (CD4-CTL) and function during the early phase of relapsing-remitting multiple sclerosis (RRMS) and in experimental autoimmune encephalomyelitis (EAE). We identify the enhanced activation of the STAT5–Runx3 axis as a key driver of CD4-CTL development and maintenance. Notably, cytotoxic activity becomes more pronounced once these cells infiltrate the central nervous system (CNS). Importantly, a cytotoxic signature in peripheral CD4⁺ T cells reliably distinguishes early-stage RRMS patients from healthy controls. Mechanistically, CD4-CTLs share core molecular programs with effector CD8⁺ T cells. Together, our findings reveal potential biomarkers for early multiple sclerosis (MS) diagnosis, tools for monitoring treatment response, and targets for novel therapeutic strategies
- Open Access
- 6 February 2024
- Published by Taylor & Francis in Research Quarterly for Exercise and Sport
- Vol. 95 (3) , 730-739
Combined Training Improves Gene Expression Related to Immunosenescence in Obese Type 2 Diabetic Individuals
Purpose: The aim of this study was to investigate the effects of moderate combined training (CT) on both the gene expression of pro- and anti-inflammatory markers and senescence in the immune system in peripheral blood mononuclear cells (PBMCs) and subcutaneous adipose tissue (SAT) of obese middle-aged individuals with type 2 diabetes (T2D). Methods: Thirty obese individuals (50.2 ± 9.4 years; body mass index: 31.8 ± 2.3 kg/m²) with T2D underwent 16 weeks of a CT group [CT; aerobic (50-60% of VO2max) plus resistance (50-75% of 1RM) training; 3 times/week, 70 min/session; n = 16)] or a control group (CG, n = 14). Nutritional patterns, muscle strength (1RM), cardiorespiratory fitness (VO2max), waist circumference (WC), body composition (Air Displacement Plethysmograph) and blood collections for biochemical (serum leptin, IL-2, IL-4, IL-6, IL-10, TNF-α and anti-CMV) and molecular (gene expression of leptin, IL-2, IL-4, IL-6, IL-10, TNF-α, PD-1, P16ink4a, CCR7, CD28 and CD27 in PBMCs and SAT) analyses were assessed before (Pre) and after (Post) the 16 weeks of the experimental period. Results: Significant decreases were observed in WC and IL4, TNF-α, PD-1 and CD27 expression in PBMCs for CT. Furthermore, significant increases were observed in 1RM and VO2max for CT after the experimental period. Conclusion: Moderate CT contributed to a reduction in the gene expression of markers associated to chronic inflammation and immunosenescence in PBMCs of obese middle-aged individuals with T2D.
- 6 February 2024
- Published by Taylor & Francis in Research Quarterly for Exercise and Sport
- Vol. 95 (3) , 730-739
Open AccessCombined Training Improves Gene Expression Related to Immunosenescence in Obese Type 2 Diabetic Individuals
Purpose: The aim of this study was to investigate the effects of moderate combined training (CT) on both the gene expression of pro- and anti-inflammatory markers and senescence in the immune system in peripheral blood mononuclear cells (PBMCs) and subcutaneous adipose tissue (SAT) of obese middle-aged individuals with type 2 diabetes (T2D). Methods: Thirty obese individuals (50.2 ± 9.4 years; body mass index: 31.8 ± 2.3 kg/m²) with T2D underwent 16 weeks of a CT group [CT; aerobic (50-60% of VO2max) plus resistance (50-75% of 1RM) training; 3 times/week, 70 min/session; n = 16)] or a control group (CG, n = 14). Nutritional patterns, muscle strength (1RM), cardiorespiratory fitness (VO2max), waist circumference (WC), body composition (Air Displacement Plethysmograph) and blood collections for biochemical (serum leptin, IL-2, IL-4, IL-6, IL-10, TNF-α and anti-CMV) and molecular (gene expression of leptin, IL-2, IL-4, IL-6, IL-10, TNF-α, PD-1, P16ink4a, CCR7, CD28 and CD27 in PBMCs and SAT) analyses were assessed before (Pre) and after (Post) the 16 weeks of the experimental period. Results: Significant decreases were observed in WC and IL4, TNF-α, PD-1 and CD27 expression in PBMCs for CT. Furthermore, significant increases were observed in 1RM and VO2max for CT after the experimental period. Conclusion: Moderate CT contributed to a reduction in the gene expression of markers associated to chronic inflammation and immunosenescence in PBMCs of obese middle-aged individuals with T2D.
- Open Access
- 17 August 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1208977
Case report: Granzyme-B expression by T- and B- cells during severe AQP4-positive Neuromyelitis Optica spectrum disorder with fatal venous thromboembolism outcome
Background: The expression of serine protease granzyme-B (GzmB) by circulating CD8+ T lymphocytes has been recently suggested as a biomarker for poor immunotherapy response and severe disability in patients with Neuromyelitis Optica spectrum disorders (NMOSD). In parallel, venous thromboembolism (VTE) has been reported mainly in NMOSD patients exhibiting transverse myelitis.Case presentation: Here, we describe an Aquaporin-4 positive (AQP4-positive) NMOSD patient who showed short myelitis (SM) and experienced a fatal pulmonary thromboembolism/lower extremity deep vein thrombosis during anti-CD20 treatment. Flow cytometry analyses from the peripheral blood revealed an enhanced cytotoxic behavior through circulating CD8+GzmB+ T, CD4+GzmB+ T lymphocytes, and residual CD19+GzmB+ B cells.Conclusions: Fatal VTE may be a rare outcome, particularly in patients exhibiting SM, and may share poorly understood immunological mechanisms with AQP4-positive NMOSD severity.
- 17 August 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1208977
Open AccessCase report: Granzyme-B expression by T- and B- cells during severe AQP4-positive Neuromyelitis Optica spectrum disorder with fatal venous thromboembolism outcome
Background: The expression of serine protease granzyme-B (GzmB) by circulating CD8+ T lymphocytes has been recently suggested as a biomarker for poor immunotherapy response and severe disability in patients with Neuromyelitis Optica spectrum disorders (NMOSD). In parallel, venous thromboembolism (VTE) has been reported mainly in NMOSD patients exhibiting transverse myelitis.Case presentation: Here, we describe an Aquaporin-4 positive (AQP4-positive) NMOSD patient who showed short myelitis (SM) and experienced a fatal pulmonary thromboembolism/lower extremity deep vein thrombosis during anti-CD20 treatment. Flow cytometry analyses from the peripheral blood revealed an enhanced cytotoxic behavior through circulating CD8+GzmB+ T, CD4+GzmB+ T lymphocytes, and residual CD19+GzmB+ B cells.Conclusions: Fatal VTE may be a rare outcome, particularly in patients exhibiting SM, and may share poorly understood immunological mechanisms with AQP4-positive NMOSD severity.
- Open Access
- 31 July 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
SARS-CoV-2 uses CD4 to infect T helper lymphocytes
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent of a major global outbreak of respiratory tract disease known as Coronavirus Disease 2019 (COVID-19). SARS-CoV-2 infects mainly lungs and may cause several immune-related complications, such as lymphocytopenia and cytokine storm, which are associated with the severity of the disease and predict mortality. The mechanism by which SARS-CoV-2 infection may result in immune system dysfunction is still not fully understood. Here, we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients. We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells. This leads to impaired CD4 T cell function and may cause cell death. SARS-CoV-2-infected T helper cells express higher levels of IL-10, which is associated with viral persistence and disease severity. Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may contribute to a poor immune response in COVID-19 patients.
- 31 July 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessSARS-CoV-2 uses CD4 to infect T helper lymphocytes
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent of a major global outbreak of respiratory tract disease known as Coronavirus Disease 2019 (COVID-19). SARS-CoV-2 infects mainly lungs and may cause several immune-related complications, such as lymphocytopenia and cytokine storm, which are associated with the severity of the disease and predict mortality. The mechanism by which SARS-CoV-2 infection may result in immune system dysfunction is still not fully understood. Here, we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients. We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells. This leads to impaired CD4 T cell function and may cause cell death. SARS-CoV-2-infected T helper cells express higher levels of IL-10, which is associated with viral persistence and disease severity. Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may contribute to a poor immune response in COVID-19 patients.
- Open Access
- 28 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8000
Defective Induction of IL-27-Mediated Immunoregulation by Myeloid DCs in Multiple Sclerosis
The purpose of this study was to examine whether myeloid dendritic cells (mDCs) from patients with multiple sclerosis (MS) and healthy controls (HCs) become similarly tolerogenic when exposed to IL-27 as this may represent a potential mechanism of autoimmune dysregulation. Our study focused on natural mDCs that were isolated from HCs and MS patient peripheral blood mononuclear cells (PBMCs). After a 24-h treatment with IL-27 ± lipopolysaccharide (LPS), the mDCs were either harvested to identify IL-27-regulated gene expression or co-cultured with naive T-cells to measure how the treated DC affected T-cell proliferation and cytokine secretion. mDCs isolated from HCs but not untreated MS patients became functionally tolerogenic after IL-27 treatment. Although IL-27 induced both HC and untreated MS mDCs to produce similar amounts of IL-10, the tolerogenic HC mDCs expressed PD-L2, IDO1, and SOCS1, while the non-tolerogenic untreated MS mDCs expressed IDO1 and IL-6R. Cytokine and RNA analyses identified two signature blocks: the first identified genes associated with mDC tolerizing responses to IL-27, while the second was associated with the presence of MS. In contrast to mDCs from untreated MS patients, mDCs from HCs and IFNb-treated MS patients became tolerogenic in response to IL-27. The genes differentially expressed in the different donor IL-27-treated mDCs may contain targets that regulate mDC tolerogenic responses.
- 28 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8000
Open AccessDefective Induction of IL-27-Mediated Immunoregulation by Myeloid DCs in Multiple Sclerosis
The purpose of this study was to examine whether myeloid dendritic cells (mDCs) from patients with multiple sclerosis (MS) and healthy controls (HCs) become similarly tolerogenic when exposed to IL-27 as this may represent a potential mechanism of autoimmune dysregulation. Our study focused on natural mDCs that were isolated from HCs and MS patient peripheral blood mononuclear cells (PBMCs). After a 24-h treatment with IL-27 ± lipopolysaccharide (LPS), the mDCs were either harvested to identify IL-27-regulated gene expression or co-cultured with naive T-cells to measure how the treated DC affected T-cell proliferation and cytokine secretion. mDCs isolated from HCs but not untreated MS patients became functionally tolerogenic after IL-27 treatment. Although IL-27 induced both HC and untreated MS mDCs to produce similar amounts of IL-10, the tolerogenic HC mDCs expressed PD-L2, IDO1, and SOCS1, while the non-tolerogenic untreated MS mDCs expressed IDO1 and IL-6R. Cytokine and RNA analyses identified two signature blocks: the first identified genes associated with mDC tolerizing responses to IL-27, while the second was associated with the presence of MS. In contrast to mDCs from untreated MS patients, mDCs from HCs and IFNb-treated MS patients became tolerogenic in response to IL-27. The genes differentially expressed in the different donor IL-27-treated mDCs may contain targets that regulate mDC tolerogenic responses.
- Open Access
- 29 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner
Visceral adiposity is a risk factor for severe COVID-19, and a link between adipose tissue infection and disease progression has been proposed. Here we demonstrate that SARS-CoV-2 infects human adipose tissue and undergoes productive infection in fat cells. However, susceptibility to infection and the cellular response depends on the anatomical origin of the cells and the viral lineage. Visceral fat cells express more ACE2 and are more susceptible to SARS-CoV-2 infection than their subcutaneous counterparts. SARS-CoV-2 infection leads to inhibition of lipolysis in subcutaneous fat cells, while in visceral fat cells, it results in higher expression of pro-inflammatory cytokines. Viral load and cellular response are attenuated when visceral fat cells are infected with the SARS-CoV-2 gamma variant. A similar degree of cell death occurs 4-days after SARS-CoV-2 infection, regardless of the cell origin or viral lineage. Hence, SARS-CoV-2 infects human fat cells, replicating and altering cell function and viability in a depot- and viral lineage-dependent fashion.
- 29 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessSARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner
Visceral adiposity is a risk factor for severe COVID-19, and a link between adipose tissue infection and disease progression has been proposed. Here we demonstrate that SARS-CoV-2 infects human adipose tissue and undergoes productive infection in fat cells. However, susceptibility to infection and the cellular response depends on the anatomical origin of the cells and the viral lineage. Visceral fat cells express more ACE2 and are more susceptible to SARS-CoV-2 infection than their subcutaneous counterparts. SARS-CoV-2 infection leads to inhibition of lipolysis in subcutaneous fat cells, while in visceral fat cells, it results in higher expression of pro-inflammatory cytokines. Viral load and cellular response are attenuated when visceral fat cells are infected with the SARS-CoV-2 gamma variant. A similar degree of cell death occurs 4-days after SARS-CoV-2 infection, regardless of the cell origin or viral lineage. Hence, SARS-CoV-2 infects human fat cells, replicating and altering cell function and viability in a depot- and viral lineage-dependent fashion.
- Open Access
- 8 February 2022
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 99, 105236
In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape
- 8 February 2022
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 99, 105236
Open AccessIn silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape
- Open Access
- 7 February 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 750660
Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients
Background: Emerging evidence of antibody-independent functions, as well as the clinical efficacy of anti-CD20 depleting therapies, helped to reassess the contribution of B cells during multiple sclerosis (MS) pathogenesis.Objective: To investigate whether CD19+ B cells may share expression of the serine-protease granzyme-B (GzmB), resembling classical cytotoxic CD8+ T lymphocytes, in the peripheral blood from relapsing-remitting MS (RRMS) patients.Methods: In this study, 104 RRMS patients during different treatments and 58 healthy donors were included. CD8, CD19, Runx3, and GzmB expression was assessed by flow cytometry analyses.Results: RRMS patients during fingolimod (FTY) and natalizumab (NTZ) treatment showed increased percentage of circulating CD8+GzmB+ T lymphocytes when compared to healthy volunteers. An increase in circulating CD19+GzmB+ B cells was observed in RRMS patients during FTY and NTZ therapies when compared to glatiramer (GA), untreated RRMS patients, and healthy donors but not when compared to interferon-β (IFN). Moreover, regarding Runx3, the transcriptional factor classically associated with cytotoxicity in CD8+ T lymphocytes, the expression of GzmB was significantly higher in CD19+Runx3+-expressing B cells when compared to CD19+Runx3- counterparts in RRMS patients.Conclusions: CD19+ B cells may exhibit cytotoxic behavior resembling CD8+ T lymphocytes in MS patients during different treatments. In the future, monitoring “cytotoxic” subsets might become an accessible marker for investigating MS pathophysiology and even for the development of new therapeutic interventions.
- 7 February 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 750660
Open AccessCytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients
Background: Emerging evidence of antibody-independent functions, as well as the clinical efficacy of anti-CD20 depleting therapies, helped to reassess the contribution of B cells during multiple sclerosis (MS) pathogenesis.Objective: To investigate whether CD19+ B cells may share expression of the serine-protease granzyme-B (GzmB), resembling classical cytotoxic CD8+ T lymphocytes, in the peripheral blood from relapsing-remitting MS (RRMS) patients.Methods: In this study, 104 RRMS patients during different treatments and 58 healthy donors were included. CD8, CD19, Runx3, and GzmB expression was assessed by flow cytometry analyses.Results: RRMS patients during fingolimod (FTY) and natalizumab (NTZ) treatment showed increased percentage of circulating CD8+GzmB+ T lymphocytes when compared to healthy volunteers. An increase in circulating CD19+GzmB+ B cells was observed in RRMS patients during FTY and NTZ therapies when compared to glatiramer (GA), untreated RRMS patients, and healthy donors but not when compared to interferon-β (IFN). Moreover, regarding Runx3, the transcriptional factor classically associated with cytotoxicity in CD8+ T lymphocytes, the expression of GzmB was significantly higher in CD19+Runx3+-expressing B cells when compared to CD19+Runx3- counterparts in RRMS patients.Conclusions: CD19+ B cells may exhibit cytotoxic behavior resembling CD8+ T lymphocytes in MS patients during different treatments. In the future, monitoring “cytotoxic” subsets might become an accessible marker for investigating MS pathophysiology and even for the development of new therapeutic interventions.